Drug appraisal enters into an era of four colors of light, and which color is yours?


The Drug Appraisal, Examine and Approve Institutional Reform Working Conferenced was hold in Shanghai. Bi Jingquan, the Director of CFDA, and Wu Zhen, the Deputy Director of CFDS were present at the conference. The conference is about polices of dealing with appraisal backlog, classify “global new” innovative drugs into district with “no color light”, classify drug that is clinical needed or good for industrial transformation into district with “green light”, classify repeated declared imitation drug into district with “yellow light”, classify restricted appraisal drug into district with “red light”, and release catalogue of restricted appraisal drug in time.